Pfizer 4Q Sales Fall
January 28 2020 - 7:30AM
Dow Jones News
By Dave Sebastian
Pfizer Inc. (PFE) reported lower fourth-quarter sales as it lost
exclusivity in its pain drug Lyrica in 2019.
The New York drugmaker on Tuesday posted $12.69 billion in
fourth-quarter sales, down from $13.98 billion in the prior year.
Analysts polled by FactSet were expecting $12.69 billion in
sales.
Sales in its Upjohn business, which includes Lyrica and
anti-impotence pill Viagra, declined 32% to $2.16 billion for the
quarter.
The company recorded net loss of $337 million, or 6 cents a
share, compared with a loss of $394 million, or 7 cents a share, in
the year-ago period.
Excluding one-time items, the company reported earnings of 55
cents a share. Analysts were looking for adjusted earnings of 58
cents a share.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
January 28, 2020 07:15 ET (12:15 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024